Search Results - "Altincatal, Arman"

Linking Ambulance Trip and Emergency Department Surveillance Data on Opioid-Related Overdose, Massachusetts, 2017 by Rahilly-Tierney, Catherine, Altincatal, Arman, Agan, Anna, Albert, Stefanie, Ergas, Rosa, Larochelle, Lauren, Yu, Jeffrey

“…Objectives Studies describing linkage of ambulance trips and emergency department (ED) visits of patients with opioid-related overdose (ORO) are limited. We…”
Get full text

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring by Calabresi, Peter A, Arnold, Douglas L, Sangurdekar, Dipen, Singh, Carol M, Altincatal, Arman, de Moor, Carl, Engle, Bob, Goyal, Jaya, Deykin, Aaron, Szak, Suzanne, Kieseier, Bernd C, Rudick, Richard A, Plavina, Tatiana

“…Objective: To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis…”
Get full text

Treatment sequences for advanced renal cell carcinoma: A health economic assessment by Deniz, Baris, Ambavane, Apoorva, Yang, Shuo, Altincatal, Arman, Doan, Justin, Rao, Sumati, Michaelson, M Dror

“…Advanced renal cell carcinoma (RCC) is commonly treated with vascular endothelial growth factor or mammalian target of rapamycin inhibitors. As new therapies…”
Get full text

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate by Scott, Thomas F., Su, Ray, Xiong, Kuangnan, Altincatal, Arman, Castrillo-Viguera, Carmen, Naylor, Maria L.

“…Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but…”
Get full text

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma by Deniz, Baris, Altincatal, Arman, Ambavane, Apoorva, Rao, Sumati, Doan, Justin, Malcolm, Bill, Michaelson, M Dror, Yang, Shuo

“…In oncology, extrapolation of clinical outcomes beyond trial duration is traditionally achieved by parametric survival analysis using population-level…”
Get full text

Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics by Hersh, Carrie M, Altincatal, Arman, Belviso, Nicholas, Kapadia, Shivani, de Moor, Carl, Rudick, Richard, Williams, James Rhys, Miller, Catherine, Koulinska, Irene

“…Background Prior studies suggest comparable effectiveness of dimethyl fumarate (DMF) and fingolimod (FTY) in multiple sclerosis (MS) using relapse, Expanded…”
Get full text

Higher maternal prenatal cortisol and younger age predict greater infant reactivity to novelty at 4 months: An observation-based study by Werner, Elizabeth, Zhao, Yihong, Evans, Lynn, Kinsella, Michael, Kurzius, Laura, Altincatal, Arman, McDonough, Laraine, Monk, Catherine

“…Distress‐linked activation of the maternal hypothalamic–pituitary–adrenal (HPA)‐axis is considered a pathway by which affect regulation impacts the fetal…”
Get full text

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma by Corren, Jonathan, Katelaris, Constance H., Castro, Mario, Maspero, Jorge F., Humbert, Marc, Halpin, David M.G., Altincatal, Arman, Pandit-Abid, Nami, Soler, Xavier, Radwan, Amr, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background The phase 3 QUEST ( NCT02414854 ) and TRAVERSE ( NCT02134028 ) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2…”
Get full text

Dementia Coding, Workup, and Treatment in the VA New England Healthcare System by Lawler, Elizabeth V., Kosik, Nicole, Altincatal, Arman, Driver, Jane A., Gagnon, David R., Cho, Kelly, Lanes, Stephan

“…Growing evidence suggests that Alzheimer’s disease and other types of dementia are underdiagnosed and poorly documented. In our study, we describe patterns of…”
Get full text

Florbetaben PET in the Early Diagnosis of Alzheimer's Disease : A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps by Guo, Shien, Getsios, Denis, Hernandez, Luis, Cho, Kelly, Lawler, Elizabeth V., Altincatal, Arman, Lanes, Stephan, Blankenburg, Michael

“…The growing understanding of the use of biomarkers in Alzheimer's disease (AD) may enable physicians to make more accurate and timely diagnoses. Florbetaben, a…”
Get full text

Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections by Bonine, Nicole Gidaya, Berger, Ariel, Altincatal, Arman, Wang, Rosa, Bhagnani, Tarun, Gillard, Patrick, Lodise, Thomas

“…To examine the clinical and economic burdens associated with delayed receipt of appropriate therapy among patients with Gram-negative bacteria (GNB)…”
Get full text

Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers by MacArthur, Robert B, Altincatal, Arman, Tuchman, Mendel

“…Background: Ammunol ® (sodium phenylacetate/sodium benzoate) is an intravenously administered, investigational drug used for the treatment of acute…”
Get full text

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies by Reder, Anthony T., Centonze, Diego, Naylor, Maria L., Nagpal, Anjali, Rajbhandari, Rajani, Altincatal, Arman, Kim, Michelle, Berdofe, Aaron, Radhakrishnan, Maha, Jung, Eunice, Sandrock, Alfred W., Smirnakis, Karen, Popescu, Catrinel, de Moor, Carl

“…Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute…”
Get full text

DUPILUMAB SHOWED CLINICAL EFFICACY IN PATIENTS WITH SEVERE ASTHMA WITH FUNGAL SENSITIZATION by CORREN, JONATHAN, HANANIA, NICOLA A, SHER, LAWRENCE D, ALTINCATAL, ARMAN, SOLER, XAVIER, PANDIT-ABID, NAMI, JACOB-NARA, JUBY A, SACKS, HARRY, ROWE, PAUL J, DENIZ, YAMO

Get full text

Consistent Efficacy Of Dupilumab In Children (6–11 years) With Type 2 Asthma Regardless Of Baseline Demographics And Disease Characteristics by Maspero, Jorge, Fiocchi, Alessandro, Deschildre, Antoine, Bacharier, Leonard, Altincatal, Arman, Laws, Elizabeth, Lederer, David, Akinlade, Bolanle, Hardin, Megan

Get full text

Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS (2392) by Hersh, Carrie M., Fitzgerald, Kathryn, Ryerson, Lana Zhovtis, Mowry, Ellen, Liao, Shirley, Altincatal, Arman, Naylor, Maria

“…Abstract only…”
Get full text

Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945) by Galetta, Steven L., Balcer, Laura J., Altincatal, Arman, Jiang, Xiaotong, Aktas, Orhan, Naylor, Maria L.

“…Abstract only…”
Get full text

Fragmentary Health Data of Patients with Multiple Sclerosis with Alternate Gender Identity (2047) by Perez-Bajandas, Coraly, Tsao, Nicole, Altincatal, Arman, Campagnolo, Denise, Castro-Borrero, Wanda

“…Abstract only…”
Get full text

Real-world Effectiveness of Dimethyl Fumarate Versus Fingolimod on Cognitive Outcomes (1798) by Hersh, Carrie, Altincatal, Arman, de Moor, Carl, Williams, James R., Miller, Catherine, Koulinska, Irene

“…Abstract only…”
Get full text

Long-Term Efficacy Of Dupilumab In Patients With Moderate-To-Severe Type 2 Asthma Stratified By Baseline Characteristics During The 96-Week TRAVERSE Study by Wechsler, Michael, Rogers, Linda, Canonica, Giorgio, Bourdin, Arnaud, Altincatal, Arman, Hardin, Megan, Soler, Xavier, Rowe, Paul, Deniz, Yamo, Sacks, Harry, Jacob-Nara, Juby

Get full text